Abstract
5-Fluorouracil (5-FU) is commonly used for the therapy of colon cancer; however, acquired resistance to 5-FU is a critical barrier to successful treatment and the primary cause of chemotherapy failure. Epithelialmesenchymal transition (EMT) is a process whereby cells undergo alterations in morphology and molecular characteristics promoting tumor progression and metastasis. Accumulating evidence shows that transition from epithelial to mesenchymal phenotype in cancer cells is associated with their resistance to chemotherapy. However, it is still poorly understood whether EMT is involved in acquired resistance to 5-FU. In this study, we developed an in vitro cell model, 5-FU-resistant HT-29 colon cancer cells, and characterized the differences in cellular morphology and molecular alterations between parental and resistant cells. In accord with mesenchymal-like morphology of 5-FU-resistant HT-29 cells, the expression of the mesenchymal marker fibronectin was significantly increased in these cells in comparision with that in the parental cells. Of interest, we also found a marked increase in the expression of EMT-inducing transcription factors Twist, Zeb1, and Zeb2. Finally, 5-FU-resistant cells showed enhanced migration in comparison with parental HT-29. Taken together, these results indicate that EMT could be associated with 5-FU resistance acquired by HT-29 cells. A specific role of each transcription factor found in this study will require further investigation.
Article PDF
Similar content being viewed by others
References
Siegel, R., Desantis, C. and Jemal, A. (2014) Colorectal cancer statistics, 2014. Ca Cancer J. Clin., 64, 104–117.
Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L. and Rougier, P. (2000) Irinote-can combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355, 1041–1047.
Longley, D.B., Harkin, D.P. and Johnston, P.G. (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 3, 330–338.
Park, I.J., You, Y.N., Agarwal, A., Skibber, J.M., Rodriguez-Bigas, M.A., Eng, C., Feig, B.W., Das, P., Krishnan, S., Crane, C.H., Hu, C.Y. and Chang, G.J. (2012) Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J. Clin. Oncol., 30, 1770–1776.
Thiery, J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2, 442–454.
Peinado, H., Olmeda, D. and Cano, A. (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer, 7, 415#x2013;428.
Kang, Y. and Massagué, J. (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell, 118, 277–279.
Vandewalle, C., Comijn, J., De Craene, B., Vermassen, P., Bruyneel, E., Andersen, H., Tulchinsky, E., Van Roy, F. and Berx, G. (2005) SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res., 33, 6566–6578.
Lombaerts, M., van Wezel, T., Philippo, K., Dierssen, J.W., Zimmerman, R.M., Oosting, J., van Eijk, R., Eilers, P.H., van de Water, B., Cornelisse, C.J. and Cleton-Jansen, A.M. (2006) E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer, 94, 661–671.
Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M.R., Lucidi, A., Ferrandina, G., Natali, P.G. and Bagnato, A. (2011) Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin. Cancer Res., 17, 2350–2360.
Rho, J.K., Choi, Y.J., Lee, J.K., Ryoo, B.Y., Na, I.I., Yang, S.H., Kim, C.H. and Lee, J.C. (2009) Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 63, 219–226.
Kajiyama, H., Shibata, K., Terauchi, M., Yamashita, M., Ino, K., Nawa, A. and Kikkawa, F. (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol., 31, 277–283.
Hiscox, S., Jiang, W.G., Obermeier, K., Taylor, K., Morgan, L., Burmi, R., Barrow, D. and Nicholson, R.I. (2006) Tamoxi-fen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int. J. Cancer, 118, 290–301.
Creighton, C.J., Li, X., Landis, M., Dixon, J.M., Neumeister, V.M., Sjolund, A., Rimm, D.L., Wong, H., Rodriguez, A., Herschkowitz, J.I., Fan, C., Zhang, X., He, X., Pavlick, A., Gutierrez, M.C., Renshaw, L., Larionov, A.A., Faratian, D., Hilsenbeck, S.G., Perou, C.M., Lewis, M.T., Rosen, J.M. and Chang, J.C. (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Pro. Natl. Acad. Sci. U.S.A., 106, 13820–13825.
Zhang, N., Yin, Y., Xu, S.J. and Chen, W.S. (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules, 13, 1551–1569.
Herrmann, R. (1996) 5-Fluorouracil in colorectal cancer, a never ending story. Ann. Oncol., 7, 551–552.
Thomson, S., Buck, E., Petti, F., Griffin, G., Brown, E., Ram-narine, N., Iwata, K.K., Gibson, N. and Haley, J.D. (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xeno-grafts to epidermal growth factor receptor inhibition. Cancer Res., 65, 9455–9462.
Byers, L.A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P.K., Nilsson, M.B., Gudikote, J., Tran, H., Cardnell, R.J., Bearss, D.J., Warner, S.L., Foulks, J.M., Kanner, S.B., Gandhi, V., Krett, N., Rosen, S.T., Kim, E.S., Herbst, R.S., Blumenschein, G.R., Lee, J.J., Lippman, S.M., Ang, K.K., Mills, G.B., Hong, W.K., Weinstein, J.N., Wistuba, I.I., Coombes, K.R., Minna, J.D. and Heymach, J.V. (2013) An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res., 19, 279–290.
Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., Campbell, L.L., Polyak, K., Brisken, C., Yang, J. and Weinberg, R.A. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704–715.
Shipitsin, M., Campbell, L.L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., Halushka, M.K., Sukumar, S., Parker, L.M., Anderson, K.S., Harris, L.N., Garber, J.E., Richardson, A.L., Schnitt, S.J., Nikolsky, Y., Gelman, R.S. and Polyak, K. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell, 11, 259–273.
Morel, A.P., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S. and Puisieux, A. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One, 3, e2888.
Li, X., Lewis, M.T., Huang, J., Gutierrez, C., Osborne, C.K., Wu, M.F., Hilsenbeck, S.G., Pavlick, A., Zhang, X., Cham-ness, G.C., Wong, H., Rosen, J. and Chang, J.C. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst., 100, 672–679.
Barr, S., Thomson, S., Buck, E., Russo, S., Petti, F., Sujka-Kwok, I., Eyzaguirre, A., Rosenfeld-Franklin, M., Gibson, N.W., Miglarese, M., Epstein, D., Iwata, K.K. and Haley, J.D. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin. Exp. Metastasis, 25, 685–693.
Singh, A. and Settleman, J. (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29, 4741–4751.
Elloul, S., Elstrand, M.B., Nesland, J.M., Tropé, C.G., Kvalheim, G., Goldberg, I., Reich, R. and Davidson, B. (2005) Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer, 103, 1631–1643.
Peña, C., García, J.M., Silva, J., García, V., Rodríguez, R., Alonso, I., Millán, I., Salas, C., de Herreros, A.G., Muñoz, A. and Bonilla, F. (2005) E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations. Hum. Mol. Genet., 14, 3361–3370.
Uchikado, Y., Okumura, H., Ishigami, S., Setoyama, T., Matsumoto, M., Owaki, T., Kita, Y. and Natsugoe, S. (2011) Increased Slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric Cancer, 14, 41–49.
Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzyk-son, R.A., Come, C., Savagner, P., Gitelman, I., Richardson, A. and Weinberg, R.A. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117, 927–939.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kim, AY., Kwak, JH., Je, N.K. et al. Epithelial-mesenchymal Transition is Associated with Acquired Resistance to 5-Fluorocuracil in HT-29 Colon Cancer Cells. Toxicol Res. 31, 151–156 (2015). https://doi.org/10.5487/TR.2015.31.2.151
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.5487/TR.2015.31.2.151